Trial · NCT01319539
Adverse events33
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 33
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Mucositis, Grade 1 | Gastrointestinal disorders | Treatment (MK2206) Dose Level 200mg | 1 | 4 | |
| other | Mucositis, Grade 1 | Gastrointestinal disorders | Treatment (MK2206) Dose Level 135mg | 0 | 3 | |
| other | Mucositis, Grade 1 | Gastrointestinal disorders | Treatment (MK2206) Dose Level 90mg | 1 | 5 | |
| other | Mucositis, Grade 2 | Gastrointestinal disorders | Treatment (MK2206) Dose Level 200mg | 2 | 4 | |
| other | Mucositis, Grade 2 | Gastrointestinal disorders | Treatment (MK2206) Dose Level 135mg | 0 | 3 | |
| other | Mucositis, Grade 2 | Gastrointestinal disorders | Treatment (MK2206) Dose Level 90mg | 1 | 5 | |
| other | Rash, Grade 2 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 200mg | 1 | 4 | |
| other | Rash, Grade 2 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 135mg | 0 | 3 | |
| other | Rash, Grade 2 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 90mg | 0 | 5 | |
| other | Rash, Grade 3 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 200mg | 1 | 4 | |
| other | Rash, Grade 3 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 135mg | 2 | 3 | |
| other | Rash, Grade 3 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 90mg | 1 | 5 | |
| other | Pruritus, Grade 1 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 200mg | 0 | 4 | |
| other | Pruritus, Grade 1 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 135mg | 1 | 3 | |
| other | Pruritus, Grade 1 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 90mg | 0 | 5 | |
| other | Pruritus, Grade 3 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 200mg | 2 | 4 | |
| other | Pruritus, Grade 3 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 135mg | 1 | 3 | |
| other | Pruritus, Grade 3 | Skin and subcutaneous tissue disorders | Treatment (MK2206) Dose Level 90mg | 0 | 5 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (MK2206) Dose Level 200mg | 2 | 4 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (MK2206) Dose Level 135mg | 0 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01319539/events